In contrast, in high-grade serous BRCA-wildtype ovarian cancer cells, prexasertib synergised with olaparib by inhibiting G2/M arrest, as well as also inhibiting olaparib-induced RAD51 foci formation [13]. The gene discussed is RAD51; the disease is ovarian carcinoma.